Kofarest-LS Syrup is a multi-ingredient pharmaceutical formulation combining Ambroxol hydrochloride (30 mg/5 ml), Levosalbutamol (1 mg/5 ml), and Guaifenesin (50 mg/5 ml) designed for the management of respiratory conditions characterized by productive cough and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscles, leading to relief from bronchospasm and improved airflow. Guaifenesin serves as an expectorant, promoting the liquefaction of mucus and enhancing its expectoration, which aids in clearing the airways. This combination is particularly beneficial in conditions such as acute and chronic bronchitis, asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders where mucus hypersecretion and bronchoconstriction coexist. Kofarest-LS Syrup should be administered as per physician’s directions, considering patient-specific factors such as age, severity of symptoms, and comorbidities. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. The syrup offers symptomatic relief by targeting multiple pathophysiological mechanisms, thereby improving respiratory function and patient comfort.